Xarelto适应症

Rivaroxaban (Xarelto) is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson. It is a highly selective oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Rivaroxaban (Xarelto) does not inhibit thrombin and has not been shown to have an effect on platelets. A dose-dependent inhibitory effect of rivaroxaban (Xarelto) on factor xa activity has been observed in humans.

Rivaroxaban (Xarelto) Indications: 1. Used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. 

The efficacy and safety of anticoagulant therapy with rivaroxaban (Xarelto, Xarelto) have been confirmed by clinical trials and involve evidence-based medicine. Unfractionated heparin requires intravenous injection, and low-molecular-weight heparin requires subcutaneous injection. Although warfarin is an oral preparation, it is easily affected by a variety of foods and drugs and requires blood laboratory testing to closely monitor the INR. These drugs are effective, but they are inconvenient to use. Compared with traditional anticoagulant drugs such as heparin and warfarin, rivaroxaban (Xarelto) is easy to take, has rapid onset of effect, does not require coagulation monitoring, and is highly safe.

The recommended dose is oral rivaroxaban (Xarelto) 10 mg once daily. If the wound has stopped bleeding, the first medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a missed dose occurs, the patient should take rivaroxaban (Xarelto) immediately and continue to take the drug once a day the next day. Patients can take rivaroxaban (Xarelto) with a meal or on its own.